Extavia® (interferon beta-1b)
Novartis Pharmaceuticals Corp.
- Administered by subcutaneous injection every other day; dose is 250 mcg.
- Approved for relapsing forms of MS and for individuals with CIS.
- Extavia is an interferon beta-1b that is biologically identical to Betaseron and made in an identical process, but marketed by a different company. It was released in early 2010.
- Extavia shares all prescribing, side effect, and safety information with Betaseron. The two pharmaceutical companies manage the patient support programs differently; prices and copayments also may vary. The latest information is available through the patient support programs at these two companies.